137 Results

People

  1. Ladanyi
    Ladanyi
  2. Rudin
    Rudin
  3. Riely
    Riely
  4. Yu
    Yu
  5. Chandarlapaty
    Chandarlapaty
  6. De Stanchina
    De Stanchina
  7. Drilon
    Drilon
  8. Chan
    Chan
  9. Hudis
    Hudis
  10. Offin
    Offin

Groups

  1. Department of Medicine (69)
  2. Solid Tumor Oncology Division (56)
  3. GSK Faculty (40)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (23)
  5. Thoracic Oncology (23)
  6. Human Oncology and Pathogenesis Program (21)
  7. Department of Pathology and Laboratory Medicine (20)
  8. Sloan Kettering Institute Postdocs (19)
  9. Hematologic Malignancies, Division of (17)
  10. Sloan Kettering Institute Faculty (15)
  1. "resistance"
Formats
  1. Journal Article (115)
  2. Meeting Abstract (9)
  3. Review (7)
  4. Conference Paper (2)
  5. Editorial (2)
  6. Book Section (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (69)
  2. Solid Tumor Oncology Division (56)
  3. GSK Faculty (40)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (23)
  5. Thoracic Oncology (23)
  6. Human Oncology and Pathogenesis Program (21)

More Groups

People
  1. Marc Ladanyi (8)
  2. Charles Rudin (7)
  3. Gregory Riely (6)
  4. Helena Yu (6)
  5. Alexander Drilon (5)
  6. Elisa De Stanchina (5)

More People

Years
  1. 2025 (2)
  2. 2024 (12)
  3. 2023 (10)
  4. 2022 (10)
  5. 2021 (10)
  6. 2020 (11)

More Years

Publications
  1. Clinical Cancer Research (12)
  2. Annals of Oncology (8)
  3. JCO Precision Oncology (8)
  4. Journal of Thoracic Oncology (7)
  5. Journal of Clinical Oncology (6)
  6. Oncogene (4)

More Publications

Publishers
  1. American Association for Cancer Research (21)
  2. Elsevier Inc. (19)
  3. American Society of Clinical Oncology (14)
  4. Oxford University Press (13)
  5. Nature Publishing Group (9)
  6. American Society for Microbiology (5)

More Publishers

Results (137)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae - A multicenter study in China
    Journal Article

    Zhang, B.; Zhu, Z.; Jia, W.; Qu, F.; Huang, B.; Shan, B.; Yu, H.; Tang, Y.; Chen, L.; Du, H.
    International Journal of Infectious Diseases (2020)

    Fulltext@MSK | Save
  • Diabetes and clinical outcome in patients with metastatic colorectal cancer: CALGB 80405 (Alliance)
    Journal Article

    Brown, J. C.; Zhang, S.; Ou, F. S.; Venook, A. P.; Niedzwiecki, D.; Lenz, H. J.; Innocenti, F.; O'Neil, B. H.; Shaw, J. E.; Polite, B. N.; more...
    JNCI Cancer Spectrum (2020)

    Fulltext@MSK | Save
  • The Human Tumor Atlas Network: Charting tumor transitions across space and time at single-cell resolution
    Editorial

    Rozenblatt-Rosen, O.; Regev, A.; Oberdoerffer, P.; Nawy, T.; Hupalowska, A.; Rood, J. E.; Ashenberg, O.; Cerami, E.; Coffey, R. J.; Demir, E.; more...
    Cell (2020)

    Fulltext@MSK | Save
  • The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients
    Journal Article

    Hallin, J.; Engstrom, L. D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D. M.; Sudhakar, N.; Bowcut, V.; Baer, B. R.; Ballard, J. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • ORCHARD: A phase II platform study in patients with advanced NSCLC who have progressed on first-line osimertinib therapy
    Meeting Abstract

    Yu, H.; Goldberg, S.; Le, X.; Piotrowska, Z.; Smith, P.; Mensi, I.; Kirova, B.; Chmielecki, J.; Li-Sucholeicki, X.; Szekeres, P.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histologic landscape of acquired resistance to osimertinib in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A.; Chan, J.; Rizvi, H.; Somwar, R.; Kubota, D.; Daneshbod, Y.; Chang, J.; Offin, M.; Arcila, M.; Pe'Er, D.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry
    Journal Article

    Mazieres, J.; Drilon, A.; Lusque, A.; Mhanna, L.; Cortto, A. B.; Mezquita, L.; Thai, A. A.; Mascaux, C.; Couraud, S.; Veillon, R.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway
    Journal Article

    Kothari, V.; Goodwin, J. F.; Zhao, S. G.; Drake, J. M.; Yin, Y.; Chang, S. L.; Evans, J. R.; Wilder-Romans, K.; Gabbara, K.; Dylgjeri, E.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save